ChemPartner
22.12.2023 22:02:41 CET | ACCESS Newswire | Press release
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Completes MQ-9B 'Flight Into Known Icing' Flight Tests20.4.2026 15:00:00 CEST | Press release
Global RPA Leader Is Certifying MQ-9B for FIKI SAN DIEGO, CA / ACCESS Newswire / April 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has conducted a series of flight tests aimed at certifying the MQ-9B Remotely Piloted Aircraft (RPA) for Flight Into Known Icing (FIKI). The flight tests began last year, and all planned testing was successfully completed in early April from GA-ASI's Flight Test & Training Center (FTTC) near Grand Forks, North Dakota, using a company-owned MQ-9B. The FIKI flights build on earlier successful flight tests to evaluate flight characteristics with simulated ice shapes adhered to the aircraft as well as the aircraft's successful Cold Weather Validation and flights in the Arctic. FIKI certification will expand MQ-9B's abilities to provide all-weather surveillance capabilities for the many nations that have purchased the system for their military and civil support missions. The tests were flown using GA-ASI Internal Research and Development fundi
GA-ASI Completes MQ-9B 'Flight Into Known Icing' Flight Tests20.4.2026 15:00:00 CEST | Press release
Global RPA Leader Is Certifying MQ-9B for FIKI SAN DIEGO, CA / ACCESS Newswire / April 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has conducted a series of flight tests aimed at certifying the MQ-9B Remotely Piloted Aircraft (RPA) for Flight Into Known Icing (FIKI). The flight tests began last year, and all planned testing was successfully completed in early April from GA-ASI's Flight Test & Training Center (FTTC) near Grand Forks, North Dakota, using a company-owned MQ-9B. The FIKI flights build on earlier successful flight tests to evaluate flight characteristics with simulated ice shapes adhered to the aircraft as well as the aircraft's successful Cold Weather Validation and flights in the Arctic. FIKI certification will expand MQ-9B's abilities to provide all-weather surveillance capabilities for the many nations that have purchased the system for their military and civil support missions. The tests were flown using GA-ASI Internal Research and Development fundi
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Loar Holdings Inc. Announces Date and Time for First Quarter 2026 Earnings and Conference Call17.4.2026 15:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / April 17, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q1 2026 earnings before the market opens on Thursday, May 7, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670/+1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact: Ian McKillop Loar Holdings Inc. Investor Relatio
Karbon-X Launches SkyXero, a New App for Flight Emissions Tracking as Travelers Seek Trusted Climate Solutions17.4.2026 15:00:00 CEST | Press release
New mobile app enables real-time flight emissions tracking and access to verified climate projects worldwide, launching during Earth Month. CALGARY, AB / ACCESS Newswire / April 17, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today announced the launch of SkyXero, a new mobile application that enables travelers to measure and balance the emissions of their flights in a few taps. Launching during Earth Month, a period of heightened global focus on environmental impact, SkyXero is now available globally and is designed to meet the growing demand from travelers seeking practical, trusted ways to incorporate climate considerations into their travel decisions. SkyXero allows users to enter flight details, instantly calculate associated emissions, and contribute to a curated portfolio of high-integrity, third-party verified climate projects, including those certi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom